Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cipla Targets Merck's Leading Anti-HIV Brand Isentress; Applies For Voluntary License In India

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Merck & Co.'s HIV integrase inhibitor Isentress (raltegravir) may have been a big success across many markets, but in India the anti-AIDS drug may be short of its mark. Leading home-grown company Cipla Ltd. has taken the route of applying for a "voluntary license" for the drug to New Jersey-headquartered Merck because Cipla says it is not reaching needy patients in India and it is priced exorbitantly

You may also be interested in...



Merck And Cipla Bury Differences To Co-market Raltegravir In India

Merck agreed to co-market its patented HIV product raltegravir in India with rival Cipla, bringing to end what had started as an attempt for a voluntary license and could have veered toward a compulsory license.

India Grants First Compulsory License To Natco For Bayer’s Nexavar; Disappointed, Bayer May Challenge Decision

India grants compulsory license to Natco for Bayer’s Nexavar; ruling could start run on more CLs.

India Grants First Compulsory License To Natco For Bayer’s Nexavar; Disappointed, Bayer May Challenge Decision

India grants compulsory license to Natco for Bayer’s Nexavar; ruling could start run on more CLs.

Related Content

UsernamePublicRestriction

Register

LL026487

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel